SCHEMBL6929995

SCHEMBL6929995

O=C1OC(c2ccc(-c3ccc(Cl)cc3Cl)cc2)C(O)=C1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.43
EDNRB P24530 1/20 0.39
EDNRA P25101 1/20 0.39
AHR P35869 1/20 0.38
MARS1 P56192 6/20 0.38
ALDH1A1 P00352 4/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
MGLL Q99685 1/20 0.37
PTGES O14684 1/20 0.37
LMNA P02545 1/20 0.37
PTGS2 P35354 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
HSD17B1 P14061 1/20 0.35
HSD17B2 P37059 1/20 0.35
ABCB1 P08183 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7589372 1.00 SRD5A2 (0.43) SRD5A2EDNRBEDNRAAHRMARS1
SCHEMBL6929961 0.84 ALDH1A1 (0.47) ALDH1A1KMT2AMEN1LMNAHPGD
SCHEMBL6929228 0.84 ALDH1A1 (0.47) ALDH1A1KMT2AMEN1LMNAHPGD
SCHEMBL7567210 0.82 ALDH1A1 (0.50) ALDH1A1KMT2AMEN1LMNAHPGD
SCHEMBL7567255 0.82 ALDH1A1 (0.50) ALDH1A1KMT2AMEN1LMNAHPGD
SCHEMBL6026250 0.82 ALDH1A1 (0.50) ALDH1A1KMT2AMEN1LMNAHPGD
SCHEMBL6933173 0.79 AHR (0.41) AHRALDH1A1KMT2AMEN1LMNA
SCHEMBL7591786 0.79 AHR (0.41) AHRALDH1A1KMT2AMEN1LMNA
SCHEMBL6930001 0.75 ALDH1A1 (0.45) ALDH1A1KMT2AMEN1LMNAHPGD
SCHEMBL6931344 0.75 ALDH1A1 (0.45) ALDH1A1KMT2AMEN1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6265436-B1 ANTIINFLAMMATORY AGENTS OXIS THERAPEUTICS INC. 2001-07-24 US claimed
EP-1246811-B1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS ISLE OF MAN LTD (GB) 2003-12-03 EP disclosed
US-6613919-B2 Resolution with enantiomerically pure bases such as cinchonidine by forming a salt; also 3,4-dihydroxy-2(5H)-furanones OXIS ISLE OF MAN 2003-09-02 US disclosed
US-20030065196-A1 Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones OXIS ISLE OF MAN 2003-04-03 US disclosed
US-6265436-B1 ANTIINFLAMMATORY AGENTS OXIS THERAPEUTICS INC. 2001-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065196-A1 Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones ADH1C, SRD5A2, SRD5A1 SRD5A2 2/4885EDNRB 2153/4885EDNRA 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.